Davita Inc vs Ishares Msci Italy ETF — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while Ishares Msci Italy ETF trades at $60.66. Which is the better fit depends on your goals.
| DVA | EWI | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $235.71 | $61.14 |
52-Week Low | $103.87 | $47.32 |
Enterprise Value | $27.47B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
EWI trades at $60.47, down 0.2% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The stock is near key resistance at $61, with support at $60. Recent news highlights Italy's economic recovery narrative and a 52-week high, though financial ratios are currently unavailable for detailed fundamental assessment.
The outlook is cautiously optimistic given technical strength and positive European market sentiment, but risks include Italy's stagflationary conditions and energy price volatility. Investment appeal hinges on continued economic improvement and resolution of macroeconomic headwinds impacting European equities.
Trailing returns across standard periods
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →